SPRYCEL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7491725 | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Mar, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8680103 | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Feb, 2025
(1 year, 4 months from now) | |
|
US8680103 (Pediatric) | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Aug, 2025
(1 year, 10 months from now) | |
|
US7491725 (Pediatric) | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Sep, 2026
(2 years from now) | |
Sprycel is owned by Bristol Myers Squibb.
Sprycel contains Dasatinib.
Sprycel has a total of 4 drug patents out of which 0 drug patents have expired.
Sprycel was authorised for market use on 28 June, 2006.
Sprycel is available in tablet;oral dosage forms.
The generics of Sprycel are possible to be released after 28 September, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 21, 2025 |
| Pediatric Exclusivity (PED) | Jun 21, 2026 |
Drugs and Companies using DASATINIB ingredient
Market Authorisation Date: 28 June, 2006
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of SPRYCEL before it's drug patent expiration?
More Information on Dosage
SPRYCEL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic